Author
Atmar, Robert LLyke, Kirsten E
Deming, Meagan E
Jackson, Lisa A
Branche, Angela R
El Sahly, Hana M
Rostad, Christina A
Martin, Judith M
Johnston, Christine
Rupp, Richard E
Mulligan, Mark J
Brady, Rebecca C
Frenck, Robert W
Bäcker, Martín
Kottkamp, Angelica C
Babu, Tara M
Rajakumar, Kumaravel
Edupuganti, Srilatha
Dobrzynski, David
Coler, Rhea N
Posavad, Christine M
Archer, Janet I
Crandon, Sonja
Nayak, Seema U
Szydlo, Daniel
Zemanek, Jillian A
Dominguez Islas, Clara P
Brown, Elizabeth R
Suthar, Mehul S
McElrath, M Juliana
McDermott, Adrian B
O'Connell, Sarah E
Montefiori, David C
Eaton, Amanda
Neuzil, Kathleen M
Stephens, David S
Roberts, Paul C
Beigel, John H
Date
2022-01-26Journal
New England Journal of MedicinePublisher
Massachusetts Medical SocietyType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1056/NEJMoa2116414https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35081293/
Abstract
In this phase 1-2, open-label clinical trial conducted at 10 sites in the United States, adults who had completed a Covid-19 vaccine regimen at least 12 weeks earlier and had no reported history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received a booster injection with one of three vaccines: mRNA-1273 (Moderna) at a dose of 100 μg, Ad26.COV2.S (Johnson & Johnson-Janssen) at a dose of 5×1010 virus particles, or BNT162b2 (Pfizer-BioNTech) at a dose of 30 μg. The primary end points were safety, reactogenicity, and humoral immunogenicity on trial days 15 and 29.Rights/Terms
Copyright © 2022 Massachusetts Medical Society.Identifier to cite or link to this item
http://hdl.handle.net/10713/18021ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa2116414
Scopus Count
Related articles
- Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
- Authors: Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM, SWITCH Research Group.
- Issue date: 2022 Mar 10
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
- Authors: Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, Salvador N, Franco MM, de Avila Mendonça RN, Queiroz Oliveira IS, de Freitas Souza BS, Fraga M, Aley P, Bibi S, Cantrell L, Dejnirattisai W, Liu X, Mongkolsapaya J, Supasa P, Screaton GR, Lambe T, Voysey M, Pollard AJ, RHH-001 study team.
- Issue date: 2022 Feb 5
- Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
- Authors: Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Islas CPD, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH, DMID 21-0012 Study Group.
- Issue date: 2021 Oct 15
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
- Authors: Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Lambe T, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Snape MD, Liu X, Faust SN, COV-BOOST study group.
- Issue date: 2021 Dec 18
- Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
- Authors: Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H
- Issue date: 2021 May 13